A Phase 3, Open-Label, Parallel Group, Multicenter, Extension Study Evaluating The Long-Term Treatment Of Bimekizumab In Study Participants With Moderate To Severe Hidradenitis Suppurativa
Posted Date: Nov 5, 2024
- Investigator: Debra Breneman
- Specialties:
- Type of Study: Drug
The purpose of this open-label extension study is to help us understand how safe and effective a new investigational drug called bimekizumab is for long-term use in treating hidradenitis suppurativa. Open label means that both you and your study doctor will know that you are receiving bimekizumab and at what dose.
Criteria:
Null
Keywords:
Hidradenitis Suppurativa
For More Information:
Jordan Sambrookes
513-475-7631
perryj8@ucmail.uc.edu